Scilex Holding (SCLX) Liabilities and Shareholders Equity (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Liabilities and Shareholders Equity of $293.6 million for Q1 2026, up 271.8% year-over-year from $79.0 million in Q1 2025, and down 19.55% quarter-over-quarter from $365.0 million in Q4 2025.
Scilex Holding (SCLX) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Scilex Holding's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $293.6 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 271.8% year-over-year to $293.6 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 170.16% YoY), while the FY2025 annual figure was $365.0 million, up 292.65% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $293.6 million, down from $365.0 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $365.0 million in Q4 2025, with the low at $79.0 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $101.3 million (2023), against an average of $138.4 million.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity slumped 38.96% in 2023, then surged 292.65% in 2025.
- Scilex Holding's Liabilities and Shareholders Equity stood at $86.5 million in 2022, then climbed by 17.08% to $101.3 million in 2023, then dropped by 8.25% to $93.0 million in 2024, then soared by 292.65% to $365.0 million in 2025, then retreated by 19.55% to $293.6 million in 2026.
- Business Quant data shows SCLX's Liabilities and Shareholders Equity at $293.6 million in Q1 2026, $365.0 million in Q4 2025, and $275.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 253.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293.64 Mn |
| Dec 31, 2025 | 364.98 Mn |
| Sep 30, 2025 | 275.88 Mn |
| Jun 30, 2025 | 83.76 Mn |
| Mar 31, 2025 | 78.98 Mn |
| Dec 31, 2024 | 92.95 Mn |
| Sep 30, 2024 | 100.43 Mn |
| Jun 30, 2024 | 104.54 Mn |
| Mar 31, 2024 | 91.24 Mn |
| Dec 31, 2023 | 101.31 Mn |
| Sep 30, 2023 | 80.53 Mn |
| Jun 30, 2023 | 126.46 Mn |
| Mar 31, 2023 | 86.05 Mn |
| Dec 31, 2022 | 86.53 Mn |
| Sep 30, 2022 | 101.46 Mn |
| Jun 30, 2022 | 142.30 Mn |
| Mar 31, 2022 | 140.97 Mn |
| Dec 31, 2021 | 77.93 Mn |
| Sep 30, 2021 | 139.64 Mn |
| Jun 30, 2021 | 139.90 Mn |